Eurofins Scientific SE

Equities

ERF

FR0014000MR3

Healthcare Facilities & Services

Market Closed - Euronext Paris Other stock markets 11:35:24 2024-05-10 am EDT			5-day change	1st Jan Change
57.66 ^EUR	+0.66%		+1.73%	-2.24%

May. 08	Corella Resources Confirms High Purity Alumina Production	MT
Apr. 29	CAC40: France's rating maintained = non-event	CF

Eurofins Scientific SE acquired an unknown majority in SARL Centre de Recherches Biologiques et d’Expérimentations Cutanées

August 02, 2022

Eurofins Scientific SE (ENXTPA:ERF) acquired an unknown majority in SARL Centre de Recherches Biologiques et d'Expérimentations Cutanées on August 3, 2022. Pascal Marchandon, Pierre Bouley and Alison Anaya of Berrylaw acted as legal advisor to Laboratoire BIO-EC. Eurofins was advised by Mermoz Avocats.

Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of an unknown majority in SARL Centre de Recherches Biologiques et d'Expérimentations Cutanées on August 3, 2022.

Latest news about Eurofins Scientific SE

Corella Resources Confirms High Purity Alumina Production	May. 08	MT
CAC40: France's rating maintained = non-event	Apr. 29	CF
CAC40: starts the week slightly up, crosses the 8100 mark	Apr. 29	CF
CAC40: interest rates soar, pulling back below 8100 pts	Apr. 24	CF
EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed	Apr. 24
CAC40: reverses course under pressure from rates at their zenith	Apr. 24	CF
CAC40: rise to 8.150, but interest-rate tensions hinder progress	Apr. 24	CF
Transcript : Eurofins Scientific SE, Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
CAC40: close to equilibrium despite Kering's plunge	Apr. 24	CF
Eurofins: organic growth close to 7% in Q1	Apr. 24	CF
Eurofins Scientific SE's Equity Buyback announced on October 3, 2022, has expired.	Apr. 23	CI
CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: week ends at half-mast, gold at its zenith	Apr. 05	CF
CAC40: pullback reduced, WStreet +0.7%, Brent at $91, Gold at $233	Apr. 05	CF
CAC40: easily preserves 8,000Pts, NFP has no impact	Apr. 05	CF
CAC40: ends the day balanced after a salvo of statistics	Apr. 04	CF
CAC40: frozen at 8,155, W-Street well disposed, gold at its zenith	Apr. 04	CF
CAC40: indecisive towards 8,160, W-Street climbs back to the top	Apr. 04	CF
EUROFINS SCIENTIFIC : Berenberg raises its price target	Apr. 04	CF
CAC40: up slightly after PMI figures	Apr. 04	CF
Eurofins Scientific to Purchase US-based Ascend Clinical	Apr. 03	MT
Eurofins completes acquisition of Ascend Clinical	Apr. 03	CF
Eurofins Scientific SE acquired Ascend Clinical, LLC.	Apr. 02	CI
CAC40: ends with a balanced performance, helped by the banking sector	Mar. 28	CF
CAC40: all-time high, tackles 8250 resistance level	Mar. 28	CF

Chart Eurofins Scientific SE

Duration

Period

More charts

Company Profile

Eurofins Scientific SE is one of the world's leading providers of bio-analytical services. The group's services are intended to validate the safety, authenticity, origin, identity, and purity of biological substances contained in the environment (water, air, soil, etc.) and in food, pharmaceutical, cosmetic, and hygiene products. At the end of 2023, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 900 laboratories located throughout the world. Net sales are distributed geographically as follows: Europe (50.7%), North America (38.5%) and other (10.8%).

Sector

Healthcare Facilities & Services

Calendar

2024-07-24 - Q2 2024 Earnings Release

Related indices

CAC 40 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed

April 24, 2024 at 11:50 am EDT

More Strategies

Ratings for Eurofins Scientific SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

57.66 EUR

Average target price

60.88 EUR

Spread / Average Target

+5.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
EUROFINS SCIENTIFIC SE	-2.24%	11.98B
HCA HEALTHCARE, INC.	+20.68%	85.55B
CVS HEALTH CORPORATION	-29.31%	70.07B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.06B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.63%	17.51B
FRESENIUS SE & CO. KGAA	+2.14%	17.39B
QUEST DIAGNOSTICS INCORPORATED	+0.39%	15.38B
REDE D'OR SÃO LUIZ S.A.	+6.47%	13.4B
NATERA, INC.	+68.09%	12.87B
FRESENIUS MEDICAL CARE AG	+6.43%	12.77B

Other Healthcare Facilities & Services